Applications of Mass Spectrometry to Membrane Protein Drug Development
Lead Research Organisation:
University of Oxford
Department Name: Oxford Chemistry
Abstract
Membrane proteins constitute the largest class of current drug targets. With many atomic structures now coming to the fore, including human protein targets, we have an unprecedented opportunity to study and rationalise the action of drugs on these important targets. One of the reasons why structures of these important proteins are only just becoming available is the inherent properties of these complexes that have hindered their study over the years; specifically their low expression levels and poor solubility contribute to the practical challenges that had to be overcome.
Now that atomic structures and mechanistic insights are emerging,new methods are therefore required to assess their drug-binding properties and to contribute to data gleaned from other biophysical methods. Mass spectrometry is one such method that is providing fascinating insight into the properties of membrane proteins. Without the complication of protective coatings, required for solubility, the gas phase can be an ideal environment for the study membrane proteins, liberated from the bilayer, but often with critical lipid binding maintained.
We are keen to develop further to our initial findings that lipids can modulate the properties of membrane proteins by extending these observations to the role of lipids and drugs simultaneously. We have selected three different themes, all of high strategic importance for drug development, described briefly here.
The ability of bacteria to resist the challenge of antibiotics is a global threat to human health. Bacteria use a variety of mechanisms to do this including through pumps embedded in cell membranes to actively expel drugs or by controlling import of drugs through pores, formed by proteins in their outer cell-envelopes. One objective of our research programme is to apply mass spectrometry to gain new insight into these two mechanisms. Specifically, we will study the roles of lipids that play in holding open pores for drug import and in speeding up the transport of drugs out through pumps.
Since many drugs now target membrane proteins a plethora of unwanted side effects are occurring through indiscriminate binding to other membrane proteins. These include binding of antipsychotic drugs to the human glucose transporter, anti HIV drugs to proteins involved in ageing and anticancer drugs to multidrug resistance pumps and to a human transporter of unknown function. A second objective is therefore to develop and apply mass spectrometry methods to study the unwanted side effects of drug binding to these targets.
A third objective of our research programme involves the study of complexes involved in the assembly and synthesis of the armoury that protects the bacterial cell envelope. Among these complexes, one folds and assembles the pore proteins and the other orchestrates the formation of peptidoglycan layer. Both are therefore attractive targets for antibiotic intervention. For example, if we could uncover new targets that prevent folding and assembly of the pore proteins we could increase their synthesis to improve drug import. Similarly if we could control synthesis of the protective peptidoglycan layer we could affect the survival of bacteria, their division and the import of drugs.
Overall therefore this research programme will have a number of beneficiaries. Firstly, it will benefit those using mass spectrometry by uncovering new methods to gain insight into the structural biology of membrane proteins. Secondly, the research outcomes will be of interest to pharmaceutical companies and biotechnology industries, particularly those with a focus on membrane protein as targets in human health or nanotechnology devices. In the longer-term interpreting mechanisms of drug resistance, unravelling the unwanted side-effects of drugs and understanding of the cell-wall biosynthesis of pathogenic bacteria will impact global human health.
Now that atomic structures and mechanistic insights are emerging,new methods are therefore required to assess their drug-binding properties and to contribute to data gleaned from other biophysical methods. Mass spectrometry is one such method that is providing fascinating insight into the properties of membrane proteins. Without the complication of protective coatings, required for solubility, the gas phase can be an ideal environment for the study membrane proteins, liberated from the bilayer, but often with critical lipid binding maintained.
We are keen to develop further to our initial findings that lipids can modulate the properties of membrane proteins by extending these observations to the role of lipids and drugs simultaneously. We have selected three different themes, all of high strategic importance for drug development, described briefly here.
The ability of bacteria to resist the challenge of antibiotics is a global threat to human health. Bacteria use a variety of mechanisms to do this including through pumps embedded in cell membranes to actively expel drugs or by controlling import of drugs through pores, formed by proteins in their outer cell-envelopes. One objective of our research programme is to apply mass spectrometry to gain new insight into these two mechanisms. Specifically, we will study the roles of lipids that play in holding open pores for drug import and in speeding up the transport of drugs out through pumps.
Since many drugs now target membrane proteins a plethora of unwanted side effects are occurring through indiscriminate binding to other membrane proteins. These include binding of antipsychotic drugs to the human glucose transporter, anti HIV drugs to proteins involved in ageing and anticancer drugs to multidrug resistance pumps and to a human transporter of unknown function. A second objective is therefore to develop and apply mass spectrometry methods to study the unwanted side effects of drug binding to these targets.
A third objective of our research programme involves the study of complexes involved in the assembly and synthesis of the armoury that protects the bacterial cell envelope. Among these complexes, one folds and assembles the pore proteins and the other orchestrates the formation of peptidoglycan layer. Both are therefore attractive targets for antibiotic intervention. For example, if we could uncover new targets that prevent folding and assembly of the pore proteins we could increase their synthesis to improve drug import. Similarly if we could control synthesis of the protective peptidoglycan layer we could affect the survival of bacteria, their division and the import of drugs.
Overall therefore this research programme will have a number of beneficiaries. Firstly, it will benefit those using mass spectrometry by uncovering new methods to gain insight into the structural biology of membrane proteins. Secondly, the research outcomes will be of interest to pharmaceutical companies and biotechnology industries, particularly those with a focus on membrane protein as targets in human health or nanotechnology devices. In the longer-term interpreting mechanisms of drug resistance, unravelling the unwanted side-effects of drugs and understanding of the cell-wall biosynthesis of pathogenic bacteria will impact global human health.
Technical Summary
Our research objective is to develop and apply mass spectrometry (MS) to drug development for membrane proteins. Specifically we will deliver new insight into drug resistance phenomena, off-pathway side-effects of drugs that bind to membrane proteins and new assemblies for antibiotic targeting. We will first look at the mechanisms operating in multi-drug resistance (MDR) efflux pumps and outer membrane porins. Together these complexes control the influx and efflux of antibiotics into, and out of, cells. Using MS, coupled with ion mobility, the simultaneous binding of drugs and lipids can be probed and their effects on the population of different conformers determined. We will use the solute carrier family of membrane proteins, also involved in MDR, to develop our drug binding strategies. Our second theme is to study the mechanism of off-pathway drug binding to membrane protein targets. To do so we will have to overcome one of the major challenges in the field: that of maintaining the stability of membrane protein drug complexes in the absence of the lipid bilayer. A third major area is characterising membrane protein assemblies that could serve as new targets for antibiotics. Here we will study complexes involved in outer membrane protein biogenesis in E. coli, specifically the beta-barrel assembly machine complex, and the lipid II flippase and elongation machinery. Both complexes play critical roles in the synthesis and assembly of bacterial cell wall components; their subunit composition, overall architecture and functional mechanisms, however, remain unclear. We will monitor oligomeric state, interaction partners and lipid binding properties of these dynamic membrane embedded machineries. Through well-established links with pharmaceutical and biotechnology companies, as well as a close working relationship with the MS industry we will be in an excellent position to exploit our research findings.
Planned Impact
Academic Community
The research described in my proposal, to develop and apply mass spectrometry (MS) to membrane proteins for drug development, will uncover many facets of the biophysics and mechanics of membrane proteins. Specifically it will inform the academic community about the synergistic role of lipids and membrane proteins, their modulation by small molecule inhibitors and their assembly into larger complexes. It will also uncover new information about the composition of key complexes involved in the synthesis of petidoglycan and in the assembly and folding of outer membrane proteins.
Our research programme will also contribute to further our understanding of the application of MS to membrane proteins and their gas phase properties. Studying drug binding in this phase, and using unfolding trajectories to inform on the stability of membrane proteins and their complexes, has not been achieved previously. Success in this area will further our understanding of this important property and will likely prove highly translational. The outcomes of this research will be published in high profile journals and will therefore highlight to the academic community the myriad of opportunities that are available for the study of membrane protein targets using MS.
In summary these academic advances will cross the traditional boundaries of chemistry, membrane protein biophysics, biochemistry and structural biology and contribute to an increased understanding of membrane proteins in the gas phase of the MS.
Economic and societal impacts The outputs of this research programme will contribute to the global competitiveness of the United Kingdom, specifically by the creation of a new spin-out company (OMASS) based on the MS of membrane proteins. This company will undertake collaborative projects based on the investigation of membrane protein targets. A number of contracts have been discussed with Amgen, Genentech, Oxford Nanopore and Roche. Two employees have been recruited to market the company and to carry out this commercial project based research. This has therefore created new employment opportunities for the UK. The PI will remain 100% research active acting as a consultant to the company but will not be involved in the day-to-day running.
Impact in membrane protein research using MS for drug development will undoubtedly have a positive effect on the competitiveness of the spin-out company and will benefit to the UK economy. Ultimately our international standing in the science and technology industries could well be affected by these developments.
For the MS industry, progress in the design and implementation of modifications for specialised research has been a hallmark of our success.
Impact on global health.
The research outlined in this proposal also has the possibility of enhance the quality of health, particularly with respect to the direct benefits gleaned from increased understanding of multidrug resistance and the unwanted side effects of drugs that bind to membrane proteins. To the best of our knowledge this is the first time this has been attempted using MS and the results will have wide ranging impact. It is often difficult to assess small molecule binding to membrane protein targets using traditional structural biology approaches, such as crystallography, primarily due to the heterogeneity of lipid, detergent and drug binding as well as the instability of many membrane protein drug complexes when isolated from the lipid bilayer.
Impact on Structural biologists
One of the other impacts for the structural biology community is the ability to monitor reconstitution of heterogeneous complexes. This has been a long-term difficulty in structural biology and is becoming increasingly apparent with the transformative developments in Cryo-EM technology. The research in this proposal in which reconstitution is monitored by MS could have far-research consequences for structural biology.
The research described in my proposal, to develop and apply mass spectrometry (MS) to membrane proteins for drug development, will uncover many facets of the biophysics and mechanics of membrane proteins. Specifically it will inform the academic community about the synergistic role of lipids and membrane proteins, their modulation by small molecule inhibitors and their assembly into larger complexes. It will also uncover new information about the composition of key complexes involved in the synthesis of petidoglycan and in the assembly and folding of outer membrane proteins.
Our research programme will also contribute to further our understanding of the application of MS to membrane proteins and their gas phase properties. Studying drug binding in this phase, and using unfolding trajectories to inform on the stability of membrane proteins and their complexes, has not been achieved previously. Success in this area will further our understanding of this important property and will likely prove highly translational. The outcomes of this research will be published in high profile journals and will therefore highlight to the academic community the myriad of opportunities that are available for the study of membrane protein targets using MS.
In summary these academic advances will cross the traditional boundaries of chemistry, membrane protein biophysics, biochemistry and structural biology and contribute to an increased understanding of membrane proteins in the gas phase of the MS.
Economic and societal impacts The outputs of this research programme will contribute to the global competitiveness of the United Kingdom, specifically by the creation of a new spin-out company (OMASS) based on the MS of membrane proteins. This company will undertake collaborative projects based on the investigation of membrane protein targets. A number of contracts have been discussed with Amgen, Genentech, Oxford Nanopore and Roche. Two employees have been recruited to market the company and to carry out this commercial project based research. This has therefore created new employment opportunities for the UK. The PI will remain 100% research active acting as a consultant to the company but will not be involved in the day-to-day running.
Impact in membrane protein research using MS for drug development will undoubtedly have a positive effect on the competitiveness of the spin-out company and will benefit to the UK economy. Ultimately our international standing in the science and technology industries could well be affected by these developments.
For the MS industry, progress in the design and implementation of modifications for specialised research has been a hallmark of our success.
Impact on global health.
The research outlined in this proposal also has the possibility of enhance the quality of health, particularly with respect to the direct benefits gleaned from increased understanding of multidrug resistance and the unwanted side effects of drugs that bind to membrane proteins. To the best of our knowledge this is the first time this has been attempted using MS and the results will have wide ranging impact. It is often difficult to assess small molecule binding to membrane protein targets using traditional structural biology approaches, such as crystallography, primarily due to the heterogeneity of lipid, detergent and drug binding as well as the instability of many membrane protein drug complexes when isolated from the lipid bilayer.
Impact on Structural biologists
One of the other impacts for the structural biology community is the ability to monitor reconstitution of heterogeneous complexes. This has been a long-term difficulty in structural biology and is becoming increasingly apparent with the transformative developments in Cryo-EM technology. The research in this proposal in which reconstitution is monitored by MS could have far-research consequences for structural biology.
Organisations
- University of Oxford (Lead Research Organisation)
- Northeastern University - Boston (Collaboration)
- University College London (Collaboration)
- HARVARD UNIVERSITY (Collaboration)
- University of Colorado Boulder (Collaboration)
- Case Western Reserve University (Collaboration)
- Newcastle University (Collaboration)
- University of California, San Francisco (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Max Planck Society (Collaboration)
- University of Hong Kong (Collaboration)
- Medical Research Council (MRC) (Collaboration)
- Rosalind Franklin Institute (Collaboration)
Publications
Landreh M
(2017)
Integrating mass spectrometry with MD simulations reveals the role of lipids in Na+/H+ antiporters.
in Nature communications
Landreh M
(2017)
Effects of Detergent Micelles on Lipid Binding to Proteins in Electrospray Ionization Mass Spectrometry.
in Analytical chemistry
Lang PA
(2022)
Studies on enmetazobactam clarify mechanisms of widely used ß-lactamase inhibitors.
in Proceedings of the National Academy of Sciences of the United States of America
Liko I
(2016)
Mass spectrometry guided structural biology.
in Current opinion in structural biology
Liu Y
(2018)
Direct binding of CEP85 to STIL ensures robust PLK4 activation and efficient centriole assembly
in Nature Communications
Marculescu C
(2019)
Probing the limits of Q-tag bioconjugation of antibodies.
in Chemical communications (Cambridge, England)
McDowell MA
(2020)
Structural Basis of Tail-Anchored Membrane Protein Biogenesis by the GET Insertase Complex.
in Molecular cell
Mehmood S
(2016)
Structural and Functional Basis for Lipid Synergy on the Activity of the Antibacterial Peptide ABC Transporter McjD.
in The Journal of biological chemistry
Title | Back cover journal illustration |
Description | Back cover journal illustration Angewandte Chemie |
Type Of Art | Artwork |
Year Produced | 2017 |
Impact | Increased interest in research |
Description | Address Scottish Parliament |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Canadian Institute for Advanced Research (CIFAR) |
Geographic Reach | North America |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | President, Royal Society of Chemistry |
Geographic Reach | National |
Policy Influence Type | Influenced training of practitioners or researchers |
Description | Covid 19 |
Amount | £20,000 (GBP) |
Organisation | University of Oxford |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2020 |
End | 12/2020 |
Description | Developing mass spectrometry to understand molecular mechanisms of antibacterial and antiviral drugs |
Amount | £1,798,744 (GBP) |
Funding ID | MR/V028839/1 |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2021 |
End | 03/2026 |
Description | MRC Confidence in Concept Round 4 |
Amount | £33,835 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2016 |
End | 08/2018 |
Title | 'Nativeomics' |
Description | A top-down method, 'nativeomics', unifying 'omics' (lipidomics, proteomics, metabolomics) analysis with native mass spectrometry. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Facilitates identification of ligands bound to membrane protein assemblies. |
Title | HDX Mass Spectrometry |
Description | Development of Hydrogen-Deuterium Exchange Mass Spectrometry to probe the conformational dynamics of a lipid sorting protein, LptDE, induced by lipids and antibiotics. |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2021 |
Provided To Others? | Yes |
Impact | As above |
Title | MS approach - annular and lipid binding to membrane proteins. |
Description | A mass spectrometry based approach to distinguish annular and specific lipid binding to membrane proteins |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | Facilitates study of membrane proteins interactions with surrounding lipids and co-factors. |
Title | Sonicated Lipid Vesicle MS 'SOLVE-MS' |
Description | A protocol that enables direct ejection of protein complexes from membranes for analysis by native MS |
Type Of Material | Improvements to research infrastructure |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Permits the study of membrane proteins directly from the membrane without the use of chemicals and allows identification of many of the loosely associated cofactors, lipids and subunits often lost with traditional methods. |
Title | Assembly and regulation of the chlorhexidine specific efflux pump AceI |
Description | Raw Mass Spectrometry data for main figures and supplementary figures for the journal article "Assembly and regulation of the chlorhexidine-specific efflux pump AceI". |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Information available to other users. |
URL | https://figshare.com/articles/Assembly_and_regulation_of_the_chlorhexidine_specific_efflux_pump_AceI... |
Title | Combining Native and 'omics' mass spectrometry to identify endogenous ligands bound to membrane proteins - RAW DATA |
Description | Raw mass spectrometry data. Figures and Extended Data forCombining Native and 'omics' mass spectrometry to identify endogenous ligands bound to membrane proteinsMain Figures 1,2,3Extended Data 3,4,5Data for supplementary figures available on request from corresponding authors |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
Impact | Data available to other users |
URL | https://figshare.com/articles/Combining_Native_and_omics_mass_spectrometry_to_identify_endogenous_li... |
Title | Solution NMR structure of the isolated NTE domain of BT1762-63 levan transporter |
Description | |
Type Of Material | Database/Collection of data |
Year Produced | 2020 |
Provided To Others? | Yes |
URL | https://bmrb.io/data_library/summary/?bmrbId=34514 |
Description | Andrew Kruse Laboratory |
Organisation | Harvard University |
Department | Harvard Medical School |
Country | United States |
Sector | Academic/University |
PI Contribution | Used native mass spectrometry to pin-point the effects of agonists, antagonists and membrane lipids on the oligomeric states of human sigma-1 receptor. |
Collaborator Contribution | Provided sigma-1 receptor and its ligands |
Impact | Manuscript for joint publication. |
Start Year | 2018 |
Description | Bharat Laboratory |
Organisation | University of Oxford |
Department | Sir William Dunn School of Pathology |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided proteins |
Impact | Generated mass spectra of CdrA protein alone and with a nanobody. Nanobodies targeting the tip of cell-surface CdrA molecules could be used to inhibit bacterial biofilm formation or disrupt pre-existing biofilms in conjunction with bactericidal antibiotics to prevent or treat problematic, chronic bacterial infections". |
Start Year | 2020 |
Description | David Julius |
Organisation | University of California, San Francisco |
Department | Department of Physiology |
Country | United States |
Sector | Academic/University |
PI Contribution | Mass spectrometry data |
Collaborator Contribution | TRP Channels |
Impact | Informative mass spectra |
Start Year | 2016 |
Description | Hongjin Zheng Laboratory |
Organisation | University of Colorado |
Country | United States |
Sector | Academic/University |
PI Contribution | Used native mass spectrometry to investigate the role of lipids on the structure and function of YbtPQ membrane transporter from uropathogenic E. coli. |
Collaborator Contribution | Provided proteins |
Impact | No outputs yet |
Start Year | 2020 |
Description | Kelly Nguyen Laboratory |
Organisation | Medical Research Council (MRC) |
Department | MRC Laboratory of Molecular Biology (LMB) |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Used native mass spectrometry to investigate subunit interactions and oligomeric state of human shelterin complex |
Collaborator Contribution | Provided proteins |
Impact | No outputs yet |
Start Year | 2020 |
Description | Lewis Laboratory |
Organisation | Northeastern University - Boston |
Country | United States |
Sector | Academic/University |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided antibiotics |
Impact | Generated mass spectrometry data; joint publication in Nature |
Start Year | 2021 |
Description | Li Laboratory |
Organisation | University of Hong Kong |
Country | Hong Kong |
Sector | Academic/University |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided antibiotics |
Impact | Mass spectra of antibiotics binding to MurJ and MraY proteins |
Start Year | 2019 |
Description | Liz Carpenter |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generated mass spectra |
Collaborator Contribution | Donation of proteins |
Impact | Publication in Cell (2018) |
Start Year | 2016 |
Description | Matthew Higgins |
Organisation | University of Oxford |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Not applicable |
Collaborator Contribution | HDX/MS |
Impact | Paper in Nature Microbiology (2018) |
Start Year | 2018 |
Description | Michel Laboratory |
Organisation | Max Planck Society |
Department | Max Planck Institute of Biophysics |
Country | Germany |
Sector | Charity/Non Profit |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided proteins and reagents |
Impact | Mass spectra of lipid binding to PfMATE protein and AI-2 binding to TqsA |
Start Year | 2019 |
Description | Naismith Laboratory |
Organisation | Rosalind Franklin Institute |
Country | United Kingdom |
Sector | Charity/Non Profit |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided proteins |
Impact | Generated mass spectra of wild type tyrosine kinase, Wzc protein and several tyrosine mutants. Enabled phosphoproteomics analysis of wild type to identify phosphorylation sites. |
Start Year | 2021 |
Description | Pepys Laboratory, Centre for Amyloidosis and Acute Phase Proteins |
Organisation | University College London |
Department | Centre for Amyloidosis and Acute Phase Proteins |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided proteins and reagents |
Impact | Mass spectra of drug binding to human CRP protein |
Start Year | 2020 |
Description | Simon Newstead |
Organisation | University of Oxford |
Department | Medical Sciences Division |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generated mass spectra |
Collaborator Contribution | Donation of proteins |
Impact | Informative mass spectra |
Start Year | 2016 |
Description | Van den Berg Laboratory |
Organisation | Newcastle University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Used native mass spectrometry to characterize enzyme-generated fructo-oligosaccharides and their binding to the SusCD transporter. |
Collaborator Contribution | Provided ligands and proteins |
Impact | Mass spectra of lipid binding to membrane proteins; Publication in Nature Communications (2021). |
Start Year | 2020 |
Description | Vollmer Laboratory |
Organisation | Newcastle University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided plasmids and reagents |
Impact | Mass spectra of lipid binding to membrane proteins. |
Start Year | 2018 |
Description | Yu |
Organisation | Case Western Reserve University |
Country | United States |
Sector | Academic/University |
PI Contribution | Generated mass spectrometry data |
Collaborator Contribution | Provided plasmids and reagents |
Impact | Joint publication in PNAS journal. |
Start Year | 2018 |
Title | DETECTION OF MEMBRANE PROTEIN-THERAPEUTIC AGENT COMPLEXES BY MASS SPECTROMETRY |
Description | According to the present invention, there is provided a method of detecting a complex comprising a membrane protein bound to a therapeutic agent by mass spectrometry. The method comprises: (a) providing a solution comprising a detergent micelle in which said complex is contained; (b) providing a mass spectrometer comprising a nanoelectrospray ionisation source, a mass analyser and a detector; (c) vaporising the solution using the nanoelectrospray ionisation source under conditions such that the complex is released from the micelle; (d) ionising the complex; (e) resolving the ionised complex using the mass analyser; and (f) detecting the resolved complex using the detector. Also provided is a solution comprising a detergent micelle in which a complex is contained, wherein the complex comprises a membrane protein bound to a therapeutic agent. |
IP Reference | WO2012172378 |
Protection | Patent granted |
Year Protection Granted | 2012 |
Licensed | No |
Impact | Interest from industry |
Company Name | OMass |
Description | OMass develops a native mass spectrometry device to discover medicines and provide insight into how potential therapeutics interact with biological ecosystems. |
Year Established | 2016 |
Impact | Series A investment from Syncona and investment from other parties. |
Website | http://www.omass.co.uk |
Company Name | OMass |
Description | OMass develops a native mass spectrometry device to discover medicines and provide insight into how potential therapeutics interact with biological ecosystems. |
Year Established | 2016 |
Impact | Interest and contracts from industry / interest from investors |
Website | http://www.omass.co.uk |
Description | 6th Molecular Microbiology Conference, Newcastle |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Engaging with scientific community |
Year(s) Of Engagement Activity | 2019 |
Description | American Society for Mass Spectrometry Online Reboot |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Fostered interest in research |
Year(s) Of Engagement Activity | 2020 |
Description | Annual Biophysical Society Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Annual lecture to Biophysical Society Members |
Year(s) Of Engagement Activity | 2019 |
Description | Astra-Zeneca Medal Award Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Other audiences |
Results and Impact | Astra-Zeneca Medal Award Lecture |
Year(s) Of Engagement Activity | 2016 |
Description | Baddiley Lecture, University of Newcastle |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | Dissemination of research results |
Year(s) Of Engagement Activity | 2017 |
Description | Bashour Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Reporting research and engaging with scientific community |
Year(s) Of Engagement Activity | 2020 |
Description | Dame Anne McLaren Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Bring research to different audiences |
Year(s) Of Engagement Activity | 2018 |
Description | Drug Target Review |
Form Of Engagement Activity | A magazine, newsletter or online publication |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Article on using native mass spectrometry to inform drug discovery. |
Year(s) Of Engagement Activity | 2017 |
URL | https://www.drugtargetreview.com/article/23594/drug-target-review-issue-2-2017/ |
Description | Empowering Women in Chemistry Event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Encourage and engage with women in Chemistry. |
Year(s) Of Engagement Activity | 2019 |
Description | Female leaders in Science Workshop |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Professional Practitioners |
Results and Impact | Workshop to discuss role of women in science leadership and provide information and advice. |
Year(s) Of Engagement Activity | 2019 |
Description | Hans Krebs Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Increased interest in MS research |
Year(s) Of Engagement Activity | 2017 |
Description | Harry G Day Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Named lecture at University of Indiana |
Year(s) Of Engagement Activity | 2016 |
Description | Host: Kuggie Vallee Distinguished Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Support of prominent women in biomedical science and discussion of some of the contemporary challenges for women building scientific careers in different parts of the world. |
Year(s) Of Engagement Activity | 2019 |
Description | Jani Reddy Bolla - Case Western |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | To share information. |
Year(s) Of Engagement Activity | 2018 |
Description | Jani Reddy Bolla Secunderabad |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | To share information. |
Year(s) Of Engagement Activity | 2018 |
Description | Joe L Franklin Memorial Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Memorial lecture in honour of Joe L Franklin, RICE, Houston Texas. |
Year(s) Of Engagement Activity | 2018 |
Description | Mabel Fitzgerald Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Bring research to different audiences |
Year(s) Of Engagement Activity | 2018 |
Description | Oxford Chemistry Alumni Event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | To discuss Chemical Sciences and vision for future. |
Year(s) Of Engagement Activity | 2019,2020 |
Description | Peter Garland Lecture, Dundee |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Postgraduate students |
Results and Impact | Dissemination of research results |
Year(s) Of Engagement Activity | 2017 |
Description | Rayson Huang Visiting Lecture, Hong Kong |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Lecture to disseminate current research. |
Year(s) Of Engagement Activity | 2019 |
Description | Structural mass spectrometry of membrane proteins |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Engaging with mass spectrometry community. |
Year(s) Of Engagement Activity | 2019 |
Description | The Making of a Scientist |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | A film to illustrate different role models and foster greater awareness to encourage more women into science. |
Year(s) Of Engagement Activity | 2018 |
Description | Torbern Bergmann Award Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Award lecture |
Year(s) Of Engagement Activity | 2016 |
Description | Webster Lecture |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Bring research to audiences |
Year(s) Of Engagement Activity | 2018 |